

Current Controversies, Recent Developments and Emerging Strategies in the Practical Management of Prostate Cancer: A Clinical Investigator Think Tank

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- The Phase III SWOG-S9346 trial reported that intermittent androgen deprivation is inferior to continuous androgen deprivation for patients with hormone-sensitive metastatic prostate cancer who have minimal disease.
 - True
 - False
- The interim analysis of the results of the COU-AA-302 Phase III trial of abiraterone acetate/prednisone versus placebo/prednisone for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) demonstrated a statistically significant improvement in _____ with abiraterone acetate.
 - Progression-free survival
 - Overall survival
 - Both a and b
- The Phase III AFFIRM trial for men with mCRPC previously treated with docetaxel demonstrated that enzalutamide was superior to placebo with respect to _____.
 - Median overall survival
 - PSA decline
 - Time to PSA progression
 - Radiographic progression-free survival
 - Quality-of-life improvement
 - All of the above
- Drug-related adverse events reported during a Phase II study of the investigational agent orteronel without prednisone for patients with nonmetastatic CRPC and rising PSA included which of the following?
 - Dyspnea
 - Hypertension
 - Fatigue
 - Hypokalemia
 - Pneumonitis
 - All of the above
- In the Phase III ALSYMPCA study, radium-223 chloride improved overall survival for patients with symptomatic CRPC with bone metastases.
 - True
 - False
- Sipuleucel-T is a(n) _____.
 - Third-generation taxane
 - Immunotherapeutic agent
 - Anti-androgen with a high affinity for the androgen receptor
- The ongoing Phase III PROSELICA trial is evaluating _____ as second-line therapy for patients with mCRPC previously treated with docetaxel.
 - Cabazitaxel at 20 mg/m²
 - Cabazitaxel at 25 mg/m²
 - Docetaxel re-treatment
 - Both a and b
 - Both a and c
- On the Phase II CUOG trial P-06c, which evaluated custirsen (OGX-011) in combination with docetaxel or mitoxantrone for patients with mCRPC progressing after first-line docetaxel, patients who received the custirsen/docetaxel combination had a longer median time to pain progression than those who received custirsen/mitoxantrone.
 - True
 - False